

Duvyzat (givinostat) oral medication was approved today by the United States Food and Drug Administration for the treatment of Duchenne Muscular Dystrophy (DMD) in individuals aged six and up. Duvyzat is the first nonsteroidal medication approved to treat patients with all genetic variations of DMD. It functions as a histone deacetylase (HDAC) inhibitor, targeting pathogenic processes to minimize inflammation and muscle loss.
“DMD denies youngsters the opportunity to live healthy lives. Emily Freilich, M.D., head of the Division of Neurology 1, Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, stated that the agency is committed to advancing the discovery of new therapeutics for Duchenne Muscular Dystrophy. “This approval provides another treatment option to help reduce the burden of this progressive, devastating disease for individuals impacted by DMD regardless of genetic mutation.”
DMD is the most common form of muscular dystrophy in childhood, affecting primarily males. Dystrophin deficiency is an uncommon neurological condition that causes increased muscular weakness. Over time, the muscles weaken, producing difficulty with walking and muscle strength, and eventually breathing problems, which lead to premature death. Life expectancy for people with DMD has grown over time, with some patients living past 30 years.
A randomized, double-blind, placebo-controlled 18-month phase 3 study was conducted to assess the efficacy of Duvyzat for the treatment of DMD. The primary outcome was muscular function change from baseline to month 18, as measured by a four-stair climb. All individuals received a standard of care steroid regimen throughout the study, and after 18 months of treatment, patients treated with Duvyzat had a statistically significant lower reduction in the time it took to ascend four stairs than placebo. The average change in time to ascend four steps from baseline to Month 18 was 1.25 seconds for patients using Duvyzat versus 3.03 seconds for placebo participants.
A secondary effectiveness goal was the change in physical function from baseline to month 18 as measured by the North Star Ambulatory Assessment (NSAA), which is a scale routinely used to score motor function in boys with DMD who can walk. After 18 months, patients who received Duvyzat experienced less NSAA score degradation than those who received a placebo.
Duvyzat’s most common side effects are diarrhea, abdominal pain, a drop in platelets (which can lead to increased bleeding), nausea/vomiting, a rise in triglycerides (a form of fat in the body), and fever.
Duvyzat’s prescribing material includes warnings stating that health care practitioners should check the patient’s platelet counts and triglycerides before prescribing the medication. Patients with a platelet count of less than 150 x 109/L should avoid taking Duvyzat. Platelet counts and triglycerides should be checked as directed during treatment to evaluate whether dosage changes are required. Dosage adjustments may also be required for moderate or severe diarrhea. Duvyzat may potentially cause QTc prolongation, increasing the risk of irregular heartbeats. Patients taking certain drugs that cause QTc prolongation or who have specific forms of heart problems should avoid Duvyzat.
The suggested dosage of Duvyzat is based on the individual’s weight. It should be given orally, twice a day, with food.
more recommended stories
Scientists Unveil Next-Gen Eye-Tracking with Unmatched Precision
Eye-tracking technology has long been a.
New Study Questions Fluid Restriction in Heart Failure Management
A groundbreaking study presented at the.
Role of Leptin Signaling in the DMH for Metabolic Regulation
A groundbreaking study from the Pennington.
COVID-19 Vaccines May Lower the Risk of Long COVID by 27%
A recent rapid review suggests that.
3D-Printed Hydrogel for Meniscus Tear Treatment
Meniscus tears are one of the.
Machine Learning Predicts Early Mortality in IBD Patients
A groundbreaking study published in the.
Endometriosis Treatment Advances: Latest Research and Therapy
Recent endometriosis treatment advances are reshaping.
Lung Cancer Screening Gaps Persist Despite Updated Guidelines
A recent study led by researchers.
Altered Knee Movement After ACL Surgery May Trigger Early Osteoarthritis
A recent study published in the.
BRP Peptide for Weight Loss: A Natural Alternative to Ozempic?
The rising obesity epidemic has fueled.
Leave a Comment